anyone following on this? looked like a safe entry point for the value divi,
W
This is what happens when you buy the peak!
Y
Cardinal Health is down 9.04% to 55.02
R
Embarrassing
W
$CAH and $CVS will be huge winners.....profitable, low valuations, inflation hedges, aging populations, government spending in health care, Covid/vaccination tail winds. Good luck longs....
Bullish
D
From CFRA -- In August, we lifted our view on shares of CAH to Buy from Hold as we think CAH is attractive at current valuations. We see CAH set for better growth in its core business in FY 22 and in the long-run we think it will likely benefit from steadily growing product volumes as baby boomers drive higher health care utilization. We view the divestiture of the Cordis business, CAH’s global manufacturer of cardiology devices for $1B as positive. The transaction is slated to close in H1 FY 22. Since its 2015 acquisition, Cordis was a significant drag for the Medical segment, in our view, due to operational problems, inventory write-downs, and mounting litigation costs. ---Consolidation of health insurers, providers, and pharmacy benefit managers has been an ongoing trend since 2018. This trend could pressure CAH's operating margins, in our view, as larger customers are able to negotiate lower distribution fees. --- Our price target is $56, 8.9x our FY 23 EPS estimate, lower than CAH’s historical forward P/ E average of 120x. Risks include a longer-thananticipated rebound in elective procedures due to new rising Covid-19 infections, severe generic price deflation and contract renewals on less favorable terms
B
At this price it's almost a 4% dividend,.great entry price!
D
4% dividend, listed as undervalued, in the growing health care market, and it is still at a 52 week low. Don't understand.
R
DUBLIN, Ohio, Aug. 11, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has extended its agreements with CVS Health to distribute pharmaceuticals to retail pharmacies and distribution centers through June 30, 2027.
Bullish
S
I'm considering initiating a position in CAH sometime over the next couple days, assuming it stays in the lower $50 range. If I buy, this will go in the more conservative portion of my IRA portfolio with plans to hold long term, reinvesting dividends along the way. Opinions, positive and negative, appreciated. Thank you!
A
One of the absolute worst healthcare stocks over the past 12 months. CAH has never recovered from last years $20 price drop.
I
3.5% dividend, 30% payout ratio, forward PE of 9. Seems like an obvious buy, like CNC was on their ER.
Opinions?
R
Just a big surprise to see the low point of the week be after such a great Earnings report. There must have been something in there that I didn't see that is a big negative. CVS is also down today, but not on the same scale as CAH.
C
From today’s WaPo: ‘Just six companies distributed 75 percent of the pills during this period: McKesson Corp., Walgreens, Cardinal Health, AmerisourceBergen, CVS and Walmart, according to an analysis of the database by The Washington Post. Three companies manufactured 88 percent of the opioids: SpecGx, a subsidiary of Mallinckrodt; Actavis Pharma; and Par Pharmaceutical, a subsidiary of Endo Pharmaceuticals. Purdue Pharma, which the plaintiffs allege sparked the epidemic in the 1990s with its introduction of OxyContin, its version of oxycodone, was ranked fourth among manufacturers with about 3 percent of the market. The volume of the pills handled by the companies skyrocketed as the epidemic surged, increasing about 51 percent from 8.4 billion in 2006 to 12.6 billion in 2012. By contrast, doses of morphine, a well-known treatment for severe pain, averaged slightly more than 500 million a year during the period.’
-- In August, we lifted our view on shares of CAH to
Buy from Hold as we think CAH is attractive at
current valuations. We see CAH set for better
growth in its core business in FY 22 and in the
long-run we think it will likely benefit from
steadily growing product volumes as baby
boomers drive higher health care utilization. We
view the divestiture of the Cordis business,
CAH’s global manufacturer of cardiology devices
for $1B as positive. The transaction is slated to
close in H1 FY 22. Since its 2015 acquisition,
Cordis was a significant drag for the Medical
segment, in our view, due to operational
problems, inventory write-downs, and mounting
litigation costs.
---Consolidation of health insurers, providers, and
pharmacy benefit managers has been an
ongoing trend since 2018. This trend could
pressure CAH's operating margins, in our view,
as larger customers are able to negotiate lower
distribution fees.
--- Our price target is $56, 8.9x our FY 23 EPS
estimate, lower than CAH’s historical forward P/
E average of 120x. Risks include a longer-thananticipated rebound in elective procedures due
to new rising Covid-19 infections, severe
generic price deflation and contract renewals on
less favorable terms
Opinions?
Purdue Pharma, which the plaintiffs allege sparked the epidemic in the 1990s with its introduction of OxyContin, its version of oxycodone, was ranked fourth among manufacturers with about 3 percent of the market.
The volume of the pills handled by the companies skyrocketed as the epidemic surged, increasing about 51 percent from 8.4 billion in 2006 to 12.6 billion in 2012. By contrast, doses of morphine, a well-known treatment for severe pain, averaged slightly more than 500 million a year during the period.’